Skip to main content
iABC_Logo_153W_100H

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)

Antimicrobial resistance (AMR) represents a serious and growing threat to human and animal health worldwide. In the EU alone, AMR is responsible for some 25 000 deaths every year, and the annual treatment and social costs have been estimated at €1.5 billion. Meanwhile, new forms of resistance continue to develop and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.

Aims

How will the iABC project help patients

Aims

Partners

Which institutions are involved in the iABC project?

Partners

Progress

What has the project achieved to date?

Progress